The filing isn't public yet. The numbers are whispers. But the signal is already loud enough to parse: Oura is seeking up to $3 billion in a US IPO at a valuation north of $16 billion.
A smart ring. A subscription fee. A data moat that competitors cannot easily replicate. That is the narrative being sold to institutional investors. But the deeper question is not whether Oura deserves a premium. It is whether the subscription model is a moat or a trap.
Proofs verify truth, but context verifies intent. Let me dissect the context.
Oura is not a hardware company. That is the first thing to understand. The ring is the entry ticket. The real product is a continuous health data feed processed by proprietary algorithms trained on over 2.5 million users' sleep, activity, and recovery patterns. This is why the market is willing to attach a multiple closer to SaaS than to consumer electronics. Recurring revenue. High gross margins. A stickier user relationship than any Apple Watch can claim.
The company reportedly generated over $500 million in revenue in 2024 with 50% year-over-year growth. Subscription penetration is estimated above 60% with a renewal rate in excess of 80%. These figures justify the narrative. But they also obscure a structural dependency that is rarely discussed: Oura's growth is now a function of subscription expansion, not hardware novelty.
That distinction matters. Hardware sales are a one-time transaction. Subscriptions are an ongoing promise. And promises are only as strong as the data behind them.
The Subscription That Binds
Oura's valuation at $16 billion implies a multiple of roughly 30x forward revenue. That is not unusual for a high-growth SaaS. But Oura is not a pure SaaS. It is a hybrid. The hardware component carries inventory risk, supply chain friction, and the brutal reality of product refresh cycles. The subscription component carries churn risk, platform dependency, and regulatory exposure.
Let me quantify the tension. A $5.99 per month subscription is trivial on its own. But the cost of acquiring a subscriber is not trivial. A $399 ring plus a subscription means the consumer pays a significant upfront fee. The hardware is the acquisition cost. The subscription is the harvest. If the ring breaks or becomes obsolete, the subscription churn follows within months.
Logic holds until the gas price breaks it. In this case, the gas price is the cost of hardware replacement. Oura Ring Gen3 was released in 2021. Gen4 followed in 2024. That is a 12-18 month refresh cycle. If a user does not upgrade, the subscription revenue continues. But if the hardware fails, the subscription ends. The hardware is the anchor. And anchors can drag.
This is the blind spot. The hardware is not a one-time asset; it is a recurring liability. Every shipped ring is a customer relationship that must be maintained. The subscription model does not eliminate hardware risk. It converts it from a transaction risk to a retention risk.
The Counter-Narrative
The mainstream reading of Oura's IPO is that it validates the health tech category. That is true. But the deeper reading is that Oura is about to face the same pressure that Apple Watch faced in 2019: market saturation.
Samsung Galaxy Ring launched in 2024. Apple Ring is rumored. Whoop is expanding beyond the wrist. The category is heating up. The first mover advantage is real. But the first mover also bears the cost of educating the market. And the market is now crowded.
Oura's positioning is sleep and recovery. That is a distinct niche. But it is also a narrow one. Sleep tracking is not a daily need. It is a periodic concern. The user who tracks their sleep for six months might not see the value in tracking it for six years. The data becomes noise. The insights become repetitive. The subscription becomes a line item to cancel.
The counter-narrative is that Oura's subscription model is a feature in the first 18 months and a liability after 24 months. The user's health data is not changing fast enough to justify continuous payment. The ROI is a diminishing curve. And no amount of algorithm improvement can change the fact that human physiology is not a dynamic system on a monthly basis.
The Data Moat Illusion
Oura's true moat is its algorithm. The dataset of 2.5 million users is a training ground for sleep and activity models that competitors lack. That is real. But it is also a snapshot. The model improves with more data. Yet the model also ages. And the market is moving to AI-native health assistants that do not rely on a single ring. The next frontier is not hardware. It is AI-driven health prediction using aggregated data from multiple sources.
Complexity hides risk; simplicity reveals it. The complexity of Oura's supply chain is hidden behind a DTC facade. The ring is manufactured in Malaysia. The components are sourced from multiple regions. The supply chain is not a moat. It is a cost center. And a liability when trade tariffs or logistics disruptions occur.
The institutional investor looking at Oura should ask a different question. Not how big the market is, but how long the subscription stays active. Not what the algorithm can do today, but what happens when a competitor trains an equivalent model on a larger dataset. Not whether the hardware is good, but whether the user replaces the ring before the subscription lapses.
The answer to these questions determines whether Oura is a $16 billion company or a $6 billion company.
The Institutional Lens
Oura has a strong brand. It has a data advantage. It has a subscription model that generates recurring revenue. These are not trivial. But the institutional due diligence should focus on three variables:
- Subscription net revenue retention (NRR) at 24 months. This is the number that determines the valuation multiple.
- Hardware refresh rate relative to subscription length. This is the number that determines the true cost of the subscription.
- Competitive response to a price war. Samsung and Apple have the power to undercut Oura's hardware and bundle subscriptions with their existing ecosystems.
In my experience auditing DeFi protocols, I learned that the best-looking metrics are often the most misleading. The same principle applies here. The revenue growth of 50% is impressive. But the question is not the growth rate. It is the growth durability. It is the cost of acquiring the next user. It is the time value of a subscriber in a market that is moving from novelty to commoditization.
The chain is fast; the settlement is slow. The smart ring market is fast. The settlement of this valuation will be slower. The IPO will price at $16 billion. The question is what the price is a year after the lockup expires.
The Takeaway
Oura is not a hardware company. It is not a SaaS company. It is a health data company with a hardware problem. The subscription is the valuation driver. But the subscription is also the risk. The user who is healthy is the user who does not need the ring. The user who is unhealthy is the user who cannot afford the subscription.
Scalability is a trade-off, not a promise. Oura is scalable because it is digital. But it is also scalable in the way that a health insurer is scalable: the more you scale, the more you are exposed to the risk of the underlying population.
The IPO is a bet on the subscription. And the subscription is a bet on the user's health being worth $5.99 a month. That is a bet I am not sure the market can price accurately.
Oura has built an impressive product. The valuation is not absurd. But the risk is not the hardware. It is not the competition. It is the subscription. And the subscription is only as strong as the user's health.